Levosimendan for postoperative subclinical heart failure after noncardiac surgery: a randomized, double-blinded, phase III trial.
Christian Reiterer, Barbara Kabon, Alexander Taschner, Alexandra Graf, Nikolas Adamowitsch, Katharina Horvath, David Emler, Oliver Zotti, Nicole Hantakova, Beatrix Hochreiter, Melanie Fraunschiel, Theresa Clement, Edith Fleischmann
Nat Commun 16(1) 5847
摘要
摘要
The effect of Levosimendan on postoperative natriuretic peptides in noncardiac surgical patients remains unknown. Thus, this study evaluates the effect of a perioperative levosimendan administration on postoperative N-terminal brain pro natriuretic peptide (NT-proBNP) concentrations. In this prospective, double-blinded, parallel group, placebo-controlled, phase III trial 115 patients were assigned to perioperative single-dose of 12.5 mg of levosimendan and 115 to placebo between October 2020 through November 2023 (clinicaltrials.gov: NCT04329624). The primary outcome was postoperative maximum NT-proBNP concentration within the first 3 postoperative days. 228 patients completed the trial. Postoperative maximum NT-proBNP concentrations did not differ significantly between the groups (effect estimate: -64.51 ng.L-1; 95% CI -332.66 to 195.56; p = 0.61). Here, we show that perioperative levosimendan administration did not lead to a significantly lower release in postoperative NT-proBNP after noncardiac surgery.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(3,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。